Flat sales at Guerbet in first nine months:
This article was originally published in Clinica
Sales at French contrast agent manufacturer Guerbet were flat at Fr 792 million ($158 million) in the first nine months of 1996. Net profits, however, were down 17% from Fr 40 million in 1995 to Fr 33 million this year. President Michel Guerbet blames cost control measures in France and a general reduction in prices. Xenetix, the company's non-ionic X-ray agent, recorded the strongest growth over the period, with sales up 400% compared with 1995. Xenetix now represents 11% of Guerbet's turnover. International sales increased 6% in the first nine months.